Tharimmune, Inc. is a biotechnology company focused on developing innovative therapies to address autoimmune diseases and other immune system-related disorders
The company leverages advanced technologies and scientific research to create targeted treatments that aim to modulate immune responses, improving patient outcomes and quality of life. Tharimmune's pipeline includes several therapeutic candidates in various stages of development, reflecting its commitment to advancing the understanding and treatment of complex immunological conditions. Through collaborations and a dedicated approach to research and development, Tharimmune aspires to make significant contributions to the field of immunotherapy.
BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQTHAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF) receptors. Using its proprietary EpiClick™ Technology, a versatile multispecific antibody engineering platform, HS1940 represents a key expansion of Tharimmune's product pipeline and underscores the Company's commitment to addressing unmet needs.
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune's Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), as well as progress on manufacturing clinical study supply.
BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.
ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a key gathering for microcap and small-cap investors, offering a platform for investment and collaboration.
Tharimmune, Inc. (NASDAQTHAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.
BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQTHAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often limited by enzymatic degradation and poor systemic circulation.
BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.
Tharimmune, Inc. (NASDAQTHAR) shares are moving higher on Wednesday after the company announced it received overall positive feedback from the European Medicines Agency (EMA) on its TH104 clinical program.
BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQTHAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a Scientific Advice meeting with the European Medicines Agency (EMA) that included guidance on a planned Phase 2 trial to advance TH104, the Company's lead clinical-stage candidate for moderate-to-severe pruritus in primary biliary cholangitis (PBC).
BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQTHAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.
- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - Merger anticipated to close in 1Q25
BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 /Tharimmune, Inc. (NASDAQTHAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab. This strategic partnership aims to expand Tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases.
BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQTHAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).
BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team.
BRIDGEWATER, NJ / ACCESSWIRE / July 16, 2024 / Tharimmune, Inc. (NASDAQTHAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announces the launch of its new website at www.tharimmune.com. This redesigned online platform provides patients, healthcare professionals and stakeholders with comprehensive information about Tharimmune's cutting-edge research, ongoing clinical trials and corporate developments.
